ABSTRACT
Non-clinical antibiotic development relies on in vitro susceptibility and infection model studies. Validating the achievement of the targeted drug concentrations is essential to avoid under-estimation of drug effects and over-estimation of resistance emergence. While certain ß-lactams (e.g., imipenem) and ß-lactamase inhibitors (BLIs; clavulanic acid) are believed to be relatively unstable, limited tangible data on their stability in commonly used in vitro media are known. We aimed to determine the thermal stability of 10 ß-lactams and 3 BLIs via LC-MS/MS in cation-adjusted Mueller Hinton broth at 25 and 36°C as well as agar at 4 and 37°C, and in water at -20, 4, and 25°C. Supplement dosing algorithms were developed to achieve broth concentrations close to their target over 24 h. During incubation in broth (pH 7.25)/agar, degradation half-lives were 16.9/21.8 h for imipenem, 20.7/31.6 h for biapenem, 29.0 h for clavulanic acid (studied in broth only), 23.1/71.6 h for cefsulodin, 40.6/57.9 h for doripenem, 46.5/64.6 h for meropenem, 50.8/97.7 h for cefepime, 61.5/99.5 h for piperacillin, and >120 h for all other compounds. Broth stability decreased at higher pH. All drugs were ≥90% stable for 72 h in agar at 4°C. Degradation half-lives in water at 25°C were >200 h for all drugs except imipenem (14.7 h, at 1,000 mg/L) and doripenem (59.5 h). One imipenem supplement dose allowed concentrations to stay within ±31% of their target concentration. This study provides comprehensive stability data on ß-lactams and BLIs in relevant in vitro media using LC-MS/MS. Future studies are warranted applying these data to antimicrobial susceptibility testing and assessing the impact of ß-lactamase-related degradation.
Subject(s)
beta-Lactamase Inhibitors , beta-Lactams , beta-Lactamase Inhibitors/pharmacology , beta-Lactams/pharmacology , Doripenem , Agar , Chromatography, Liquid , Tandem Mass Spectrometry , Anti-Bacterial Agents/pharmacology , Penicillins , Clavulanic Acid/pharmacology , Imipenem/pharmacology , Water , Microbial Sensitivity TestsABSTRACT
In dairy operations, antibiotics have traditionally been used to treat, prevent, and control diseases. However, given the mounting global crisis of antimicrobial resistance (AMR), farmers are urged to re-assess and reduce their reliance on antibiotics. Thus, this randomized, double-blinded cohort study aimed to estimate the prevalence of failed and successful transfer of passive immunity (FTPI and STPI) in dairy goat kids reared under commercial conditions, and the effects of antibiotic metaphylaxis on the pre-weaning (≤42 d old) mortality in FTPI and STPI kids. Plasma concentration of immunoglobulin G at 1d old (pIgG-24 h) was measured in 747 male Saanen kids for the determination of FTPI and STPI (pIgG-24 h < 12 and ≥12 g/L, respectively). Kids were then randomly divided into two groups: those receiving a single penicillin injection at 1 d old (PEN), and those receiving no treatment (CTR). The mean (±SD) pIgG-24 h and initial BW (IBW) were 17 ± 9.8 g/L and 4.1 ± 0.64 kg. The prevalence of FTPI was 29% (220/747 kids). Gastrointestinal complications were the primary cause of death (41%), followed by septicemia (22%) and arthritis (17%). A single penicillin injection reduced preweaning mortality by 55% (10 vs 22%, PEN vs CTR). However, results suggest that such a decline was mainly driven by the improved survival rates among FTPI kids, which increased by 19% (from 62% in CTR-FTPI to 82% in PEN-FTPI), as opposed to an 8% increase among STPI kids (from 85% in CTR-STPI to 93% in PEN-STPI). Additionally, the odds of mortality ≤ 42 d old were threefold higher in the CTR-FTPI group when compared to both the CTR-STPI and PEN-FTPI groups, suggesting a potential parity between STPI and PEN for mortality rate reduction. Taken together, the results indicate that although metaphylactic antibiotics can halve preweaning mortality, similar improvements are likely to be achieved via increased STPI rates. Furthermore, by targeting metaphylactic interventions to high-risk groups (i.e., those displaying signs of inadequate colostrum intake and/or low birth BW), farmers could reduce treatment costs and mitigate AMR risks. While these findings carry considerable weight for commercial dairy goat practices, their applicability to other systems (i.e., extensive, semi-intensive, mohair, meat systems) warrants further investigation.
Subject(s)
Animals, Newborn , Goats , Immunity, Maternally-Acquired , Immunoglobulin G , Animals , Female , Male , Pregnancy , Animals, Newborn/blood , Animals, Newborn/immunology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Cohort Studies , Colostrum/immunology , Goats/blood , Goats/immunology , Immunoglobulin G/blood , Penicillins , Drug Resistance, BacterialABSTRACT
BACKGROUND: Pharmacokinetic (PK) data underlying paediatric penicillin dosing remain limited, especially in critical care. OBJECTIVES: The primary objective of the Neonatal and Paediatric Pharmacokinetics of Antimicrobials study (NAPPA) was to characterize PK profiles of commonly used penicillins using data obtained during routine care, to further understanding of PK variability and inform future evidence-based dosing. METHODS: NAPPA was a multicentre study of amoxicillin, co-amoxiclav, benzylpenicillin, flucloxacillin and piperacillin/tazobactam. Patients were recruited with informed consent. Antibiotic dosing followed standard of care. PK samples were obtained opportunistically or at optimal times, frozen and analysed using UPLC with tandem MS. Pharmacometric analysis was undertaken using NONMEM software (v7.3). Model-based simulations (nâ=â10â000) tested PTA with British National Formulary for Children (BNFC) and WHO dosing. The study had ethical approval. RESULTS: For the combined IV PK model, 963 PK samples from 370 participants were analysed simultaneously incorporating amoxicillin, benzylpenicillin, flucloxacillin and piperacillin data. BNFC high-dose regimen simulations gave these PTA results (median fT>MIC at breakpoints of specified pathogens): amoxicillin 100% (Streptococcus pneumoniae); benzylpenicillin 100% (Group B Streptococcus); flucloxacillin 48% (MSSA); and piperacillin 100% (Pseudomonas aeruginosa). Oral population PK models for flucloxacillin and amoxicillin enabled estimation of first-order absorption rate constants (1.16 h-1 and 1.3 h-1) and bioavailability terms (62.7% and 58.7%, respectively). CONCLUSIONS: NAPPA represents, to our knowledge, the largest prospective combined paediatric penicillin PK study undertaken to date, and the first paediatric flucloxacillin oral PK model. The PTA results provide evidence supportive of BNFC high-dose IV regimens for amoxicillin, benzylpenicillin and piperacillin.
Subject(s)
Floxacillin , Piperacillin , Infant, Newborn , Humans , Child , Adolescent , Piperacillin/pharmacokinetics , Amoxicillin , Prospective Studies , Anti-Bacterial Agents/therapeutic use , Penicillins , Microbial Sensitivity TestsABSTRACT
OBJECTIVES: The blaZ gene encodes penicillinase, which inactivates penicillin. As there were reports on suboptimal sensitivity for the penicillin zone-edge test, a phenotypic method for blaZ detection, we investigated treatment outcomes in patients with penicillin-susceptible Staphylococcus aureus (PSSA) bacteraemia (phenotypically negative for penicillinase), subjecting isolates to molecular testing for blaZ retrospectively. PATIENTS AND METHODS: A retrospective cohort study was conducted on 121 patients with a first episode of PSSA bacteraemia from 1 January 2012 to 31 October 2015 at Tan Tock Seng Hospital (TTSH), Singapore. Patients were grouped into IV benzylpenicillin and non-benzylpenicillin groups. The primary outcome was overall treatment failure, defined as either 30 day all-cause mortality and/or 90 day relapse. The penicillin (P10) zone-edge test was repeated on archived PSSA isolates, concurrently with penicillin MIC determination via gradient diffusion and PCR for blaZ. RESULTS: Among 121 patients, 57 patients (47.1%) received IV benzylpenicillin as the predominant antibiotic. There was no significant difference in overall treatment failure between treatment with the benzylpenicillin [7/57 (12.3%)] versus non-benzylpenicillin groups [12/64 (18.8%)] (Pâ=â0.33) or cloxacillin/cefazolin [6/37 (16.2%)] (Pâ=â0.59). For 112 PSSA isolates available for testing, repeat penicillin zone-edge testing was negative for penicillinase production, corroborating previous results. A single PSSA isolate with a negative penicillin zone-edge test was found to be positive for blaZ. CONCLUSIONS: We found no differences in overall treatment failure between patients with PSSA bacteraemia treated with benzylpenicillin, anti-staphylococcal ß-lactams cefazolin/cloxacillin and other antimicrobials, when using the penicillin zone-edge test as the phenotypic method for blaZ screening.
Subject(s)
Bacteremia , Staphylococcal Infections , Humans , Anti-Bacterial Agents/therapeutic use , Penicillins/therapeutic use , Staphylococcus aureus/genetics , Retrospective Studies , Cefazolin , Penicillinase , Penicillin G/therapeutic use , Staphylococcal Infections/drug therapy , Bacteremia/drug therapy , Treatment Outcome , Cloxacillin , Microbial Sensitivity TestsABSTRACT
Newer materials for utilization in multi-directional therapeutic actions are investigated, considering delicate design principles involving size and shape control, surface modification, and controllable drug loading and release. Multi-faceted properties are imparted to the engineered nanoparticles, like magnetism, near-infrared absorption, photothermal efficiency, and suitable size and shape. This report presents nickel sulfide and dysprosium-doped nickel sulfide nanoparticles with poly-ß-cyclodextrin polymer coating. The nanoparticles belong to the orthorhombic crystal systems, as indicated by X-ray diffraction studies. The size and shape of the nanoparticles are investigated using Transmission Electron Microscope (TEM) and a particle-size analyzer. The particles show soft ferromagnetic characteristics with definite and moderate saturation magnetization values. The nickel sulfide nanoparticles' in vitro anticancer and antibacterial activities are investigated in free and 5-fluorouracil/penicillin benzathine-loaded forms. The 5-fluorouracil-encapsulation efficiency of the nanoparticles is around 87%, whereas it is above 92% in the case of penicillin benzathine. Both drugs are released slowly in a controlled fashion. The dysprosium-doped nickel sulfide nanoparticles show better anticancer activity, and the efficacy is more significant than the free drug. The nanoparticles are irradiated with a low-power 808 nm laser. The dysprosium-doped nickel sulfide nanoparticles attain a higher temperature on irradiation, i.e., above 59 °C. The photothermal conversion efficiency of this material is determined, and the significance of dysprosium doping is discussed. Contrarily, the undoped nickel sulfide nanoparticles show more significant antibacterial activity. This study presents a novel designed nanoparticle system and the exciting variation of properties on dysprosium doping in nickel sulfide nanoparticles.
Subject(s)
Hyperthermia, Induced , Nanoparticles , Dysprosium , Nanoparticles/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Fluorouracil , Penicillins , PhototherapyABSTRACT
MOTIVATION: Drug combination therapy shows significant advantages over monotherapy in cancer treatment. Since the combinational space is difficult to be traversed experimentally, identifying novel synergistic drug combinations based on computational methods has become a powerful tool for pre-screening. Among them, methods based on deep learning have far outperformed other methods. However, most deep learning-based methods are unstable and will give inconsistent predictions even by simply changing the input order of drugs. In addition, the insufficient experimental data of drug combination screening limits the generalization ability of existing models. These problems prevent the deep learning-based models from being in service. RESULTS: In this article, we propose CGMS to address the above problems. CGMS models a drug combination and a cell line as a heterogeneous complete graph, and generates the whole-graph embedding to characterize their interaction by leveraging the heterogeneous graph attention network. Based on the whole-graph embedding, CGMS can make a stable, order-independent prediction. To enhance the generalization ability of CGMS, we apply the multi-task learning technique to train the model on drug synergy prediction task and drug sensitivity prediction task simultaneously. We compare CGMS's generalization ability with six state-of-the-art methods on a public dataset, and CGMS significantly outperforms other methods in the leave-drug combination-out scenario, as well as in the leave-cell line-out and leave-drug-out scenarios. We further present the benefit of eliminating the order dependency and the discrimination power of whole-graph embeddings, interpret the rationality of the attention mechanism, and verify the contribution of multi-task learning. AVAILABILITY AND IMPLEMENTATION: The code of CGMS is available via https://github.com/TOJSSE-iData/CGMS.
Subject(s)
Penicillins , Drug Combinations , Cell Line , Drug Evaluation, PreclinicalABSTRACT
The use of antibiotics in semen extenders can contribute to the development of antibiotic resistance. The objective of the study was to evaluate epsilon-polylysine (Æ-PL) as a substitute for antibiotics in the buffalo semen extender. For this, 20 semen ejaculates were collected from four Murrah buffalo bulls. Each ejaculate was divided into three equal aliquots and extended into an egg yolk-based semen extender containing either antibiotics (strepto-penicillin) or different concentrations of Æ-PL (0.64 and 1.28 g/L) to make the final concentration 80 million sperm/mL and cryopreserved as per the standard procedure. The antibiogram sensitivity test confirmed that Æ-PL is an effective antimicrobial against microbes present in buffalo semen ejaculates. Furthermore, the addition of Æ-PL in the semen extender significantly reduces the colony forming unit (CFU)/mL in cryopreserved semen equivalent to strepto-penicillin. The sperm motility and kinematic parameters assessed by a computer-assisted sperm analyser showed that Æ-PL did not inhibit either sperm motility not kinematic parameters of cryopreserved sperm. The flow-cytometric evaluation of frozen-thawed sperm revealed interesting results. The extender supplemented with Æ-PL protected sperm acrosome and mitochondrial membrane potential greater than the extender supplemented with strepto-penicillin. Further, Æ-PL reduced significantly the production of superoxide anions from mitochondria during the cryopreservation process. In this way, Æ-PL may be a suitable alternative to antibiotics in semen extenders. In conclusion, Æ-PL at a concentration of 0.64 g/L acts as an effective antimicrobial as well as antioxidant in semen extender for cryopreservation of buffalo sperm.
Subject(s)
Semen Preservation , Semen , Male , Animals , Lysine/pharmacology , Semen Analysis/veterinary , Sperm Motility , Semen Preservation/veterinary , Semen Preservation/methods , Cryoprotective Agents/pharmacology , Spermatozoa , Cryopreservation/veterinary , Cryopreservation/methods , Anti-Bacterial Agents/pharmacology , Drug Resistance, Microbial , Penicillins , BuffaloesABSTRACT
ABSTRACT: Antibiotics are frequently reported as allergies by patients, particularly antibiotics from the penicillin family. Most of these reported allergies are benign, and the consequences of alternative therapies can be significant. This article provides background information on penicillin allergies and serves as a guide to penicillin allergy management.Reprinted with permission from Wrynn, A.F. An overview of penicillin allergies for nurses. Nurse Pract 2022; 47(9): 30-36. Copyright Wolters Kluwer. All rights reserved.
Subject(s)
Drug Hypersensitivity , Hypersensitivity , Nurses , Humans , Anti-Bacterial Agents/adverse effects , Penicillins/adverse effects , Drug Hypersensitivity/drug therapy , Hypersensitivity/drug therapyABSTRACT
OBJECTIVE: To assess the association between preconception antibiotic use and fecundability, the per menstrual cycle probability of conception. DESIGN: SnartForaeldre.dk, a Danish prospective cohort study of women trying to conceive (2007-2020). SETTING: Not applicable. SUBJECT(S): 9462 female participants, median age 29 years at enrollment. EXPOSURE: Antibiotic use was defined by filled prescriptions retrieved from the Danish National Prescription Registry, using Anatomical Therapeutic Chemical codes, and modeled as time-varying (menstrual cycle-varying) exposure. MAIN OUTCOME MEASURE(S): Pregnancy status was reported on female follow-up questionnaires every 8 weeks for up to 12 months or until conception. Fecundability ratios (FR) and 95% confidence intervals (CI) were computed using proportional probabilities regression models, with adjustment for age, partner age, education, smoking, folic acid supplementation, body mass index, parity, cycle regularity, timing of intercourse, and sexually transmitted infections. RESULT(S): During all cycles of observation, the percentage of participants filing at least 1 antibiotic prescription was 11.9%; 8.6% had a prescription for penicillins, 2.1% for sulfonamides, and 1.8% for macrolides. Based on life-table methods, 86.5% of participants conceived within 12 cycles of follow-up. Recent preconception antibiotic use was associated with reduced fecundability (≥1 prescription vs. none: adjusted FR = 0.86; 95% CI, 0.76-0.99). For participants using penicillins, sulfonamides, or macrolides, the adjusted FRs were 0.97 (95% CI, 0.83-1.12), 0.68 (95% CI, 0.47-0.98), and 0.59 (95% CI, 0.37-0.93), respectively. CONCLUSION(S): Preconception use of antibiotics, specifically sulfonamides and macrolides, was associated with decreased fecundability compared with no use. The observed associations may be explained plausibly by confounding by indication, as we lacked data on indications for the prescribed antibiotics. Consequently, we cannot separate the effect of the medication from the effect of the underlying infection.
Subject(s)
Anti-Bacterial Agents , Fertility , Pregnancy , Female , Humans , Adult , Prospective Studies , Anti-Bacterial Agents/adverse effects , Sulfanilamide/pharmacology , Penicillins/pharmacology , Denmark/epidemiologyABSTRACT
Drug-resistant microorganisms are defeated using combinational drug delivery systems based on biopolymer chitosan (CS) and metal nanoparticles. Hence, PEGylated zinc oxide nanoparticles (P-ZnO NPs) decorated chitosan-based nanoparticles (CS NPs) were prepared to deliver ampicillin (AMP) for improved antibacterial activity. In comparison to ZnO NPs, P-ZnO NPs exhibit less aggregation and more stable rod morphologies in TEM. The size of the P-ZnO NPs decreased and was engulfed by the spherical CS-AMP NPs. The zeta potential of the CS-AMP-P-ZnO NPs was determined to be -32.93 mV and the hydrodynamic size to be 210.2 d. nm. Further, DEE and DLE of CS-AMP (2.0:0.2 w/w) showed 79.60 ± 2.62 % and 15.14 ± 2.11 %, respectively. The cumulative AMP release was observed at >50 % at 48 h at pH 5.4 and 7.4. Additionally, when compared to AMP, CS-AMP-P-ZnO NPs had better antibacterial activity against E. coli, due to the alternation of cell membrane permeability by CS and ZnO NPs. Moreover, the hemolytic properties of ZnO NPs were attenuated because of PEGylation and CS. Furthermore, due to the biocompatible behavior of CS, CS-AMP-P-ZnO NPs did not exhibit toxicity on HEK-293 cells, erythrocytes, and chick embryos. Hence, this study concludes that CS-AMP-P-ZnO NPs could be a promising antibacterial agent.
Subject(s)
Chitosan , Metal Nanoparticles , Nanoparticles , Zinc Oxide , Humans , Animals , Chick Embryo , Chitosan/chemistry , Zinc Oxide/chemistry , Nanoparticle Drug Delivery System , Escherichia coli , HEK293 Cells , Anti-Bacterial Agents/chemistry , Penicillins , Nanoparticles/chemistry , Metal Nanoparticles/chemistry , Ampicillin , Microbial Sensitivity TestsABSTRACT
The incidence of syphilis has been increasing in the USA since 2000. Notably, the coronavirus disease 2019 pandemic negatively impacted the public health efforts to contain the spread of sexually transmitted diseases including syphilis and congenital syphilis. Clinical manifestations of syphilis are predominantly mucocutaneous lesions, thus dermatologists are primed to recognize the myriad presentations of this disease. Primary syphilis is classically characterized by a painless transient chancre most often located in the genital area. Secondary syphilis typically manifests clinically as systemic symptoms in addition to a mucocutaneous eruption of which a variety of forms exist. Although less common in the era of effective penicillin treatment, late clinical manifestations of syphilis are described as well. In addition to recognition of syphilis on physical examination, several diagnostic tools may be used to confirm infection. Treponema pallidum spirochetes may be detected directly using histopathologic staining, darkfield microscopy, direct fluorescent antibody, and polymerase chain reaction assays. A table detailing the histopathologic features of syphilis is included in this article. Serologic testing, non-treponemal and treponemal tests, is the preferred method for screening and diagnosing syphilis infections. Two serologic testing algorithms exist to aid clinicians in diagnosing positive syphilis infection. Determining the correct stage of syphilis infection combines results of serologic tests, patient history, and physical examination findings. Using the current Centers for Disease Control and Prevention case definitions and treatment guidelines, a management algorithm is proposed here. Penicillin remains the pharmacological treatment of choice although specific clinical situations allow for alternative therapies. Syphilis is a reportable disease in every state and should be reported by stage according to individual state requirements. Screening recommendations are largely based upon risks encountered through sexual exposures. Likewise, sexual partner management includes evaluating and treating persons exposed to someone diagnosed with an infective stage of syphilis. Close clinical follow-up and repeat testing are recommended to ensure appropriate response to treatment. This guide will discuss the current epidemiology of syphilis and focus on practice aspects of diagnosis and management, including public health reporting.
Subject(s)
COVID-19 , Dermatology , Syphilis , Humans , Syphilis/complications , Syphilis/diagnosis , Syphilis/epidemiology , COVID-19/complications , Treponema pallidum , Penicillins/therapeutic useABSTRACT
The emergence of methicillin-resistant Staphylococcus aureus (MRSA) has become a critical global concern. Identifying new anti-S. aureus agents or therapeutic strategies are urgently needed to treat S. aureus infection. The present study investigated the antibacterial activity of 16 phenolic compounds against MRSA, four of which exhibited antibacterial activity. Their antibacterial activities increased in a dose-dependent manner but showed different responses with the extension of treatment time. Trialdehyde phloroglucinol (TPG) and 2-nitrophloroglucinol (NPG) maintained stable antibacterial activity; however, that of dichlorophenol and myricetin decreased rapidly over 24 hr of treatment. Checkerboard and time-kill assays indicated that TPG and NPG exhibited strong synergistic antibacterial activities with penicillin or bacitracin. Microscopic observation and membrane integrity analysis showed that the combination of TPG and penicillin destroyed the MRSA cell membrane, resulting in the leakage of intracellular biomacromolecules, marked changes in surface zeta potential, and the collapse of membrane potential. Moreover, the combination significantly decreased penicillinase activity and penicillin-binding protein 2a mRNA expression, inhibiting MRSA growth. Taken together, these results demonstrated that the combination of the phloroglucinol derivative TPG and penicillin has significant synergistic anti-MRSA activity and can serve as a potential therapeutic strategy to treat MRSA infections.
Subject(s)
Anti-Bacterial Agents , Methicillin-Resistant Staphylococcus aureus , Anti-Bacterial Agents/pharmacology , Drug Synergism , Microbial Sensitivity Tests , Penicillins/pharmacology , Staphylococcus aureus , Phloroglucinol/pharmacologyABSTRACT
To report on the therapy used for penicillin- and cephalosporin-resistant pneumococcal meningitis, we conducted an observational cohort study of patients admitted to our hospital with pneumococcal meningitis between 1977 and 2018. According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations, we defined pneumococci as susceptible and resistant to penicillin with MIC values of ≤0.06 mg/L and > 0.06 mg/L, respectively; the corresponding values for cefotaxime (CTX) were ≤0.5 mg/L and >0.5 mg/L. We treated 363 episodes of pneumococcal meningitis during the study period. Of these, 24 had no viable strain, leaving 339 episodes with a known MIC for inclusion. Penicillin-susceptible strains accounted for 246 episodes (73%), penicillin-resistant strains for 93 (27%), CTX susceptible for 58, and CTX resistant for 35. Nine patients failed or relapsed and 69 died (20%), of whom 22% were among susceptible cases and 17% were among resistant cases. During the dexamethasone period, mortality was equal (12%) in both susceptible and resistant cases. High-dose CTX (300 mg/Kg/day) helped to treat failed or relapsed cases and protected against failure when used as empirical therapy (P = 0.02), even in CTX-resistant cases. High-dose CTX is a good empirical therapy option for pneumococcal meningitis in the presence of a high prevalence of penicillin and cephalosporin resistance, effectively treating pneumococcal strains with MICs up to 2 mg/L for either penicillin or CTX.
Subject(s)
Cephalosporins , Meningitis, Pneumococcal , Humans , Cephalosporins/therapeutic use , Cephalosporins/pharmacology , Meningitis, Pneumococcal/drug therapy , Penicillins/pharmacology , Penicillins/therapeutic use , Ceftriaxone/pharmacology , Cohort Studies , Cefotaxime/therapeutic use , Cefotaxime/pharmacology , Streptococcus pneumoniae , Microbial Sensitivity Tests , Monobactams/pharmacology , Penicillin Resistance , Mitomycin/pharmacology , Mitomycin/therapeutic use , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic useABSTRACT
Noncholera vibriosis is a rare, opportunistic bacterial infection caused by Vibrio spp. other than V. cholerae O1/O139 and diagnosed mainly during the hot summer months in patients after seaside activities. Detailed knowledge of circulating pathogenic strains and heterogeneities in infection outcomes and disease dynamics may help in patient management. We conducted a multicenter case-series study documenting Vibrio infections in 67 patients from 8 hospitals in the Bay of Biscay, France, over a 19-year period. Infections were mainly caused by V. alginolyticus (34%), V. parahaemolyticus (30%), non-O1/O139 V. cholerae (15%), and V. vulnificus (10%). Drug-susceptibility testing revealed intermediate and resistant strains to penicillins and first-generation cephalosporins. The acute infections (e.g., those involving digestive disorder, cellulitis, osteitis, pneumonia, and endocarditis) led to a life-threatening event (septic shock), amputation, or death in 36% of patients. Physicians may need to add vibriosis to their list of infections to assess in patients with associated risk factors.
Subject(s)
Vibrio Infections , Vibrio cholerae , Vibrio , Humans , Bays , Vibrio Infections/drug therapy , Vibrio Infections/epidemiology , Penicillins , Multicenter Studies as TopicABSTRACT
Neonatal sepsis is a life-threatening emergency, and empirical antimicrobial prescription is common. In this cross-sectional study of neonates admitted with suspected sepsis in a teaching hospital in Ghana from January-December 2021, we described antimicrobial prescription patterns, compliance with national standard treatment guidelines (STG), blood culture testing, antimicrobial resistance patterns and treatment outcomes. Of the 549 neonates admitted with suspected sepsis, 283 (52%) were males. Overall, 529 (96%) received empirical antimicrobials. Most neonates (n = 407, 76.9%) were treated empirically with cefuroxime + gentamicin, while cefotaxime was started as a modified treatment in the majority of neonates (46/68, 67.6%). Only one prescription complied with national STGs. Samples of 257 (47%) neonates underwent blood culture testing, of which 70 (27%) were positive. Isolates were predominantly Gram-positive bacteria, with coagulase-negative Staphylococcus and Staphylococcus aureus accounting for 79% of the isolates. Isolates showed high resistance to most penicillins, while resistance to aminoglycosides and quinolones was relatively low. The majority of neonates (n = 497, 90.5%) were discharged after successfully completing treatment, while 50 (9%) neonates died during treatment. Strengthening of antimicrobial stewardship programmes, periodic review of STGs and increased uptake of culture and sensitivity testing are needed to improve management of sepsis.
Subject(s)
Anti-Infective Agents , Quinolones , Sepsis , Anti-Bacterial Agents/therapeutic use , Cefotaxime , Cefuroxime , Coagulase , Cross-Sectional Studies , Female , Gentamicins , Ghana/epidemiology , Hospitals, Teaching , Humans , Infant, Newborn , Male , Microbial Sensitivity Tests , Penicillins , Sepsis/drug therapy , Sepsis/epidemiologyABSTRACT
Medicinal herbs have been used as traditional treatments for many pathogens and extracted bioactive compounds from medicinal plants with a suitable therapeutic index for the production of new drugs. Moreover, they are utilized to evaluate different concentrations of aqueous and alcoholic extracts of Averrhoa bilimbi leaves and antibiotics against bacteria isolated from the oral cavity. This study was conducted simultaneously at the Departments of Botany and Biology, Shatrah Hospital, Thi-Qar, Iraq, during March and August 2021. A. bilimbi leaf extracts were utilized in the plant component examination and the assessment of the antibacterial activity. The bacterial strain of Escherichia coli and Klebsiella pneumoniae was isolated from the oral cavity. To test the antibacterial impact of the extracts on bacteria, the agar well diffusion method was used. The phytochemical screening indicated the presence of Alkaloids, Flavonoids, Sapiens, Steroids, Tannins, Glycosides, and Carbohydrates, followed by the absence of Tannins in aqueous extract. Due to the A. bilimbi leaf aqueous and methanol extract against E. coli, areas of inhibition were found (0.20 cm and 0.19 cm) at the concentration of 100 mg/ml, respectively. However, there were no regions of inhibition of the K. pneumoniae trend for both extracts. The sensitivity of bacterial isolates of E. coli and K. pneumonia to antibiotics was also tested through Gentamicin, Amoxycillin, Azithromycin, Ciprofloxacin, Penicillin, and Polymyxin B, and the regions of inhibition appeared against E. coli (0.5cm, 0 cm, 0.34 cm, 0.45 cm, 0 cm, and 0.12 cm, respectively). Furthermore, the regions of inhibition appeared against K. pneumoniae (3 cm, 0.3 cm, 0.4 cm, 0.55 cm, 0 cm, 0.66 cm, respectively). The antibiotics showed a higher inhibition zone, compared to the aqueous and alcoholic extracts; however, further studies are required to be conducted to validate its reliability.
Subject(s)
Alkaloids , Averrhoa , Agar , Alkaloids/chemistry , Alkaloids/pharmacology , Amoxicillin , Anti-Bacterial Agents/pharmacology , Azithromycin , Bacteria , Ciprofloxacin , Escherichia coli , Flavonoids/pharmacology , Gentamicins , Glycosides , Methanol , Microbial Sensitivity Tests , Mouth , Penicillins , Phytochemicals/pharmacology , Phytochemicals/chemistry , Plant Extracts/pharmacology , Plant Extracts/chemistry , Polymyxin B , Reproducibility of Results , Tannins/pharmacology , HumansABSTRACT
The paper presents results of AI diagnostics and treatment across the period of 2004-2020 pointing to the efficacy of two particular protocols. METHOD: Quantitative determination of amanitins in blood (ATOs) and urine (ATOu) performed by the original ELISA kit, indicated upon mycological history and clinical symptoms of poisoning. ATOu positive cases were recommended our protocol; ATOu negative results excluded amanitin poisoning. RESULTS: out of 2876 fungal poisonings registered in Slovakia during the subjected period, were 698 AI suspected cases. In 557 of them, was AI reliably excluded, in 141 confirmed. Urinary ATOu correlated with the severity of poisoning in the range of 6-47 h after mushroom ingestion, without false negativity. Serum ATOs had no diagnostic value. 129 patients with confirmed AI received full treatment protocol with antidotes of penicillin plus silibinin. In this group died two patients of acute kidney injury in the early stages of poisoning and 127 patients were recovered. Silibinin without penicillin was used in 12 patients. One of them undergone liver transplantation and four patients died of fulminant liver failure, respectively intracranial hemorrhage. Treatment failure in the PNC + silibinin protocol was 1.5 % (2 of 127 patients), silibinin alone being 41.7 % (5 of 12 patients, p = 0.00058). CONCLUSION: Early diagnostics of amanitin intoxication based on mycological and clinical history and subsequent determination of urinary amanitin levels (ATOu) allows early initiation of treatment. The use of treatment protocol with antidotes of PNC and silibinin is of high therapeutic efficacy. The omission of PNC from the treatment protocol significantly worsens patients' prognosis.
Subject(s)
Antidotes , Mushroom Poisoning , Humans , Antidotes/therapeutic use , Silybin/therapeutic use , Slovakia/epidemiology , Mushroom Poisoning/diagnosis , Mushroom Poisoning/therapy , Amanita , Amanitins , Penicillins/therapeutic useABSTRACT
ABSTRACT: Antibiotics are frequently reported as allergies by patients, particularly antibiotics from the penicillin family. Most of these reported allergies are benign, and the consequences of alternative therapies can be significant. This article will deliver background information on penicillin allergies and serve as a guide to penicillin allergy management.
Subject(s)
Drug Hypersensitivity , Penicillins , Anti-Bacterial Agents/adverse effects , Drug Hypersensitivity/drug therapy , Humans , Penicillins/adverse effectsABSTRACT
The aim of this study was to investigate how the application of vitamin E affected the levels of chemical elements in the brain tissues of epilepsy-induced rats. The sample of 40 adult male rats was separated into 4 equal groups: Group 1: control, Group 2: vitamin E; Group 3: penicillin to promote epileptic form activity and Group 4: penicillin + vitamin E. After three months of treatment, an Atomic Absorption Spectrophotometer was used to analyze the presence of the elements in brain tissue sections (brain, brainstem, cerebellum) of the decapitated animals. The levels of magnesium in the groups that received vitamin E (G2 and 4) were significantly higher than in the control group (G1) and the first epilepsy group (G3) (p.05).Chrome and zinc levels in brain, brainstem, and cerebellum tissue of the two epilepsy groups (G3-4) decreased significantly compared to the control group (G1) and the vitamin E group (G2) (p.05). The levels of copper in the brainstem and lead in the cerebellum of the first epilepsy group (G3) were higher than in all other groups (p.05). The findings showed that the application of vitamin E in experimental epilepsy may have a limited effect on element metabolism in brain tissue. A decline in zinc levels in the brain, brainstem and cerebellum tissues in epilepsy groups constitutes another result of our study. This should be examined further to determine whether decreased levels of zinc play a role in epilepsy pathogenesis.
Subject(s)
Epilepsy , Animals , Brain , Dietary Supplements , Epilepsy/drug therapy , Epilepsy/metabolism , Male , Penicillins/pharmacology , Rats , Vitamin E/pharmacology , Zinc/metabolism , Zinc/pharmacologyABSTRACT
BACKGROUND: Today, despite the existence of various chemical and physical treatments for wound healing, the use of traditional medicine including herbal medicine is still widely used in most developed and developing countries. OBJECTIVES: To investigate the antimicrobial and wound-healing activities of alcoholic extract of Boswellia carterii (BC) plant. METHODS: The BC extract was prepared using alcohol 70%. The chemical groups and extract compounds were determined using Fourier transform infrared spectroscopy (FTIR) and high-performance liquid chromatography (HPLC) analysis, respectively. The antimicrobial and wound-healing activities of different concentrations of BC extract and its combination with penicillin-streptomycin were assessed by agar well diffusion and infected wound model in albino rabbits, respectively. RESULTS: FTIR revealed the presence of hydroxyl, amide, carboxyl, alkyl C-H stretches, aromatic C=C bends, and aromatic C-H bends in the BC extract. The HPLC revealed 14 different compounds including thujene (48.0%) as the most abundant ingredient. All BC concentrations showed antibacterial and wound-healing activities. The 10% concentration of BC extract had the strongest antibacterial effect. Also, the combination of penicillin-streptomycin with BC extract showed synergistic antibacterial effect. The 5% concentration of BC was the best wound-healing compound which healed the wound in 6 days and decreased the wound size 10 mm each day. CONCLUSIONS: This study demonstrated the potential abilities of BC as an antibacterial and wound-healing medicinal plant. Further studies are required to justify the in vivo use of this plant.